Abstract. Small non-protein coding RNAs that regulate messenger RNA levels, namely microRNAs (miRNAs), have been implicated in the pathogenesis of various diseases. The purpose of the present study was to identify essential miRNAs involved in lung carcinogenesis. Previous studies demonstrated that an investigation into the downstream targets of oncogenic KRAS could be used as a strategy to elucidate the molecular mechanisms involved in lung cancer; therefore, we examined the expression profiles of mRNAs modulated by oncogenic KRAS in the present study. We focused on miR-31 from the miRNAs that were differentially expressed, and evaluated its potential role in the development of lung cancer. miR-31 was upregulated not only by oncogenic KRAS, but also by oncogenic EGFR. The expression of miR-31 was markedly attenuated in some lung cancer cell lines by deleting its host gene locus. The restoration of miR-31 in lung cancer cell lines that lost its expression attenuated their growth activities. The knockdown of miR-31 expression in lung cancer cell lines retaining its expression enhanced anchorage-independent growth activity. These results suggest that miR-31 may be a suppressor that regulates an essential oncogenic pathway, the loss of which may promote lung carcinogenesis.
Introduction
Lung cancer is one of the most common causes of cancer-related mortality in the developed world (1, 2) . Recurrence has been reported in a large proportion of lung cancer patients in spite of successful resection of the primary tumor (1, 2) . Although some lung tumors are known to be sensitive to conventional chemotherapeutic agents or certain molecular targeting agents, many are not (3, 4) . Thus, further understanding of the molecular mechanisms involved in lung carcinogenesis is essential for developing novel therapeutic strategies.
Our previous studies, which involved a comprehensive search for the downstream targets of oncogenic KRAS, identified important molecules involved in lung carcinogenesis (3, 5) . Mutations in driver oncogenes, such as KRAS, EGFR, BRAF, and ALK, were found to mutually and exclusively occur, and each of these mutations has been shown to transmit the common essential oncogenic signal that promotes carcinogenesis (6) (7) (8) . Therefore, the downstream targets of oncogenic KRAS participate not only in KRAS-mediated carcinogenesis, but also in other oncogene-mediated carcinogeneses (3, 5) . Thus, an investigation into the downstream targets of oncogenic KRAS is considered to be an available strategy that can identify common important molecular mechanisms involved in lung cancer.
Small non-protein coding RNAs that regulate messenger RNA levels, namely microRNAs (miRNAs), have been identified and subsequently implicated in the pathogenesis of various diseases. The present study investigated the expression profiles of miRNAs modulated by oncogenic KRAS in airway epithelial cells. We focused on miR-31 from the miRNAs that were differentially expressed, and evaluated its potential role in the development of lung cancer.
Materials and methods
Cell lines and culture. An immortalized human airway epithelial cell line [16HBE14o, simian virus 40 (SV40)-transformed human bronchial epithelial cells] described by Cozens et al (9) was kindly provided by D.C. Grunert (California Pacific Medical Center Research Institute). A sub-clone of 16HBE14o cells, described as NHBE-T in this study, was used. Human lung cancer cell lines (A549, H358, H2087, H23, EKVX, H226, H827, H1819, H441, H4006, HOP62, H1299 and H460) and a human embryonic kidney cell line (HEK293T) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). The human lung cancer cell line LC2/ad was purchased from the Riken Cell Bank (Tsukuba, Japan). The human lung cancer cell lines, PC1, PC9 and HARA were
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from Immuno-Biological Laboratories Co. (Gunma, Japan). The human lung cancer cell lines, TKB1, TKB2, TKB4, TKB5,  TKB6, TKB7, TKB8, TKB14 and TKB20 were obtained from dr Hiroshi Kamma via dr Takuya Yazawa (Kyorin University School of Medicine) (10) . Primary small airway epithelial cells (SAEC) were purchased from Sanko Kagaku (Tokyo, Japan).
Plasmid construction. The pro-retrovirus vector bearing KRAS [wild-type (WLD), V12, H61, V12/S35, V12/G37 and V12/C40 mutants] (11) and PIK3CA (WLD, E545K mutant, and H1047R mutant) were previously described (12) .
Complementary dNA (cdNA) coding EGFR (NM_001964) and BRAF (NM_004333) was PCR-amplified using cDNA from NHBE-T cells as a template and inserted into the pro-retrovirus vector pQCXIP (BD Clontech, Palo Alto, CA, USA). Mutant EGFR (deletion: E745-A750) was PCR-amplified using cdNA from the PC9 lung cancer cell line. EGFR (L858R mutant) and BRAF (V600E mutant) were generated by the method of site-directed mutagenesis. dNA fragments including the miR-31 coding region (MIMAT0000089) flanking approximately a 100 base-pair margin in both directions was PCR-amplified and inserted into the pro-retrovirus vector pLHCX (BD Clontech). Vectors bearing a sense and antisense strand of cdNA were obtained. A pNsi-based miR-31 blocking vector was purchased from Takara Bio Inc.
(Kyoto, Japan).
Retroviral-mediated gene transfer.
The pro-retrovirus vectors bearing the desired constructs and the pLC10A1 retroviruspackaging vector (Imgenex, San diego, CA, USA) were cotransfected into HEK293T cells with Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA). Forty-eight hours after the transfection, conditioned medium was recovered as a viral solution. The desired genes were introduced by incubating cells with the viral solution containing 10 µg/ml of polybren (Sigma, St. Louis, MO, USA). Cells stably expressing the desired genes were selected with 250 µg/ml of hygromycin B or 1,000 µg/ml of neomycin (both from Invitrogen). The pooled clones were used for analyses as follows.
miRNA expression profiling. miRNA expression profiles in empty vector (MOCK)-, KRAS/WLd-, KRAS/V12-, and KRAS/H61-vector transduced NHBE-T cells were comprehensively evaluated with human miRNA microarray (Human miRNA Microarray kit release 16.0, 8x60K, cat. no. G4870A; Agilent Technologies, Santa Clara, CA, USA). Total RNA was extracted from the cells immediately after completing the selection (5 days post-transduction) using the RNA easy kit (Qiagen, Hilden, Germany). Labeling and hybridization was performed according to the manufacturer's recommendations (Agilent Technologies).
Colony formation assays. Cells (appropriate count of 1.0x10 4 to 5.0x10 4 ) were seeded onto a 10 cm culture dish (Iwaki, Tokyo, Japan), and grown for 10 days. Cells were fixed with methanol and Giemsa-stained, and colonies visible in scanned images were counted.
Growth curve assays. Cells (2.5x10 5 ) were seeded onto a 10 cm culture dish, and were grown in dMEM (Sigma) with 10 FBS (Sigma) to a semi-confluent state for 5-7 days. Cells were counted, and 2.5x10 5 cells were seeded again onto a 10 cm dish. Several passages were repeated in the same manner. The sum of population doublings (PdLs) at each point was calculated by the formula SPdL n = log 2 (count n /2.5x10 5 ) + SPdL n-1 .
Soft agar colony formation assays. Cells (1.25x10 4 ) were cultured and grown in 1 ml of dMEM-based 0.3% agar (agar noble; Becton-dickinson, Sparks, Md, USA) containing 10% FBS in 3.5 cm culture dishes (Iwaki) for 4 weeks. The agars were fixed with a buffered 4% paraformaldehyde solution, and colonies visible in scanned images were counted.
Treatment with an inhibitor for MEK and PI3K.
Following infection of the retrovirus vector, cells stably expressing KRAS were selected for 3 days, and were then harvested. Cells were treated with an inhibitor for MEK (PD98059, 50 µM) or PI3K (LY294002, 50 µM) [both from Cell Signaling Technology (CST), danvers, MA, USA] and their combination for the last 24 h before the harvest.
Comprehensive search for the downstream target of miR-31.
Gene expression in the empty vector (MOCK)-, miR-31 sense strand (SS)-, and miR-31 antisense (AS) strandtransduced NHBE-T cells was comprehensively evaluated with a human gene chip microarray (SurePrint G3 Human Gene Expression 8x60K v2 Microarray kit, cat. no. G4851B; Agilent Technologies). Total RNA was extracted from the cells immediately after completing the selection (5 days post-transduction) using the RNA easy kit (Qiagen). Labeling and hybridization were performed according to the manufacturer's recommendations (Agilent Technologies). Transcripts whose signal values in the miR-31 SS-transduced cells were 5-fold higher or lower than that in both the empty vector-transduced cells and the miR-31 antisense strand-transduced cells were extracted according to the same flow chart as described in a previous study (13) . 
Results

miRNA expression profiling modulated by oncogenic KRAS.
A comprehensive evaluation of the expression of miRNA revealed that oncogenic KRAS-transduced cells had different expression profiles from empty vector-and WLD KRAStransduced cells, as KRAS/V12-and KRAS/H61-transduced cells were classified into a distant branch from the others on a dendrogram described by hierarchical clustering analysis (Fig. 1 ). The miRNAs that had higher or lower levels in oncogenic KRAS (KRAS/V12 and KRAS/H61)-transduced cells than in both mock (MOCK)-and WLd KRAS (KRAS/WLd)-transduced cells are listed in Table I . Quantitative RT-PCR analysis confirmed that the transduction of oncogenic KRAS induced the largest change in let-7i and miR-31 (Fig. 2) . Therefore, we focused on these two miRNAs.
Let-7i and miR-31 expression in lung cancer cell lines. Let-7i
and miR-31 expression levels were analyzed by quantitative RT-PCR analysis. Let-7i was expressed at various levels in all the cells examined. Let-7i levels were higher in cancer cell lines than in non-cancerous immortalized cell lines and primary airway epithelial cells (Fig. 3) . In contrast, miR-31 expression levels were lower in cancer cell lines, and some cell lines [27.5%, 11/40, the loss of miR-31 expression was frequently detected in LCC cell lines (80.0%, 4/5)] completely lost its expression (Fig. 2) . These results prompted us to further investigate the potential significance of the loss of miR-31 expression in lung carcinogenesis.
Effect of the restoration and knockdown of miR-31 on cell growth.
The restoration of the miR-31 SS, but not the antisense strand, markedly suppressed the growth of cancer cell lines that lost miR-31 expression, as it decreased the formation of colonies and prolonged the doubling time (Fig. 4 , TKB1 and H441 cells were examined. A representative result in TKB1 cells is shown). On the other hand, the knockdown of miR-31 expression in cell lines that retained its expression resulted in an enhancement in their growth activities in both ordinary media and soft agar ( Comprehensive search for potential genes modulated by miR-31. A comprehensive evaluation of gene expression profiles revealed that miR-31 SS-transduced cells had a different expression profile from empty vector (mock)-and miR-31 antisense strand (AS)-transduced cells, as miR-31SS-transduced cells were classified into the most distant branch on a dendrogram described from a hierarchical clustering analysis (Fig. 6 ). Transcripts with expression levels that were >5-fold higher in miR-31SS-transduced cells than in mock-and miR-31AS-transduced cells were extracted (Tables II and III) .
Involvement of different oncogenic pathways in the induction of miR-31.
The expression of miR-31 was also induced by the transduction of oncogenic EGFR [deletion mutation (deletion: E746-A750), point mutation L858R], but not by oncogenic BRAF (V600E) or oncogenic PIK3CA (E545K, H1047R) (Fig. 7) . The expression of miR-31 was consistently not induced by specific mutants in KRAS that activated MEK, RAL-GDS or PI3K (Fig. 7) . Inhibitors for MEK (the BRAF-MEK-ERK pathway) or PI3Kinase (the PIK3CA-mediated pathway) interfered with the induction of miR-31 by oncogenic KRAS.
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Discussion
The findings of an initial study on breast cancer suggested that miR-31 could be a tumor suppressor that especially inhibited the invasive and metastatic spread of neoplastic cells (14) . Previous studies have supported this initial observation and identified the potential molecular mechanisms responsible for the inhibition of invasion and metastasis by miR-31 (15) . miR-31 was also shown to be downregulated in gastric cancer and was suggested to function as a tumor suppressor (16) . In contrast, previous studies reported that miR-31 was upregulated in colorectal cancer and may also promote the invasive and metastatic spread of neoplastic cells (17, 18) . Thus, the potential role of miR-31 in carcinogenesis may differ depending on the type of cancer. The expression of miR-31 in lung cancer has generally been reported to be higher in tumor tissue than in the corresponding non-tumorous tissue (19) (20) (21) (22) (23) (24) (25) . However, miR-31 levels have been shown to vary in primary lung tumors. Some tumors expressed miR-31 at lower levels than the corresponding non-tumorous tissue or did not express it at all. miR-31 expression was markedly reduced or completely lost in some lung cancer cell lines (Fig. 3) . This result suggested that miR-31 may be a suppressor in lung carcinogenesis. The restoration of miR-31 in lung cancer cell lines that had lost its expression markedly attenuated their growth activities (Fig. 4) . The knockdown of miR-31 expression in cell lines that retained its expression enhanced oncogenic phenotypes such as anchorage-independent growth activity (Fig. 5) . These results supported miR-31 being a suppressor. However, a recent study demonstrated the oncogenic role of miR-31 in lung carcinogenesis using experiments with different cell lines from the ones used in the present study (26) . miR-31 may play a pleiotropic role in the development of individual tumors. Further investigations are required to resolve this issue. In the present study, miR-31 was upregulated not only by oncogenic KRAS, but also by oncogenic EGFR in vitro (Fig. 7) . Neither oncogenic BRAF nor oncogenic PIK3CA induced its expression (Fig. 7) . Similarly, the specific mutant of KRAS that activated the MEK-mediated pathway only and another specific mutant that activated the PI3K-mediated pathway only did not induce the expression of miR-31 (Fig. 7) . On the other hand, the MEK inhibitor, but not PI3K inhibitor, attenuated the oncogenic KRAS-induced expression of miR-31 (Fig. 7) . These results suggest that miR-31 could be a common player that regulates the KRAS/EGFR-mediated essential oncogenic pathway (Fig. 8) . The MEK-mediated pathway may be necessary, but not sufficient for the induction of miR-31 expression (Fig. 8) . The PI3K-mediated pathway may not be involved in its regulation (Fig. 8) . A novel pathway may be inducing the expression of miR-31 in cooperation with the MEK-mediated pathway.
This comprehensive search for the potential target of miR-31 revealed that the downregulated transcripts included many molecules mediating the cytokine/chemokine signaling pathway (Tables II and III) . TNFSF15, in particular, has been published on an online site as the predicted downstream target for miR-31 (http://mirdb.org/miRDB/index.html). TNFSF15, a member of the tumor necrosis factor (TNF) and TNF receptor superfamilies, regulates cell growth and apoptosis in an autocrine manner, and has been reported to suppress cancer cell growth by inhibiting angiogenesis (27) . Thus, TNFSF15 could be a factor that participates in miR-31-induced growth modulations. Future studies that focus on the potential downstream targets of miR-31 may provide insight into the molecular mechanisms involved in lung cancer.
The present study comprehensively searched miRNAs, the expressions of which were regulated by oncogenic KRAS, and focused on miR-31 in order to investigate its potential involvement in lung carcinogenesis. The expression of miR-31 was markedly attenuated in lung cancer cell lines. The restoration of miR-31 in lung cancer cell lines that lost its expression attenuated their growth activities. The knockdown of miR-31 expression in cell lines that retained its expression enhanced oncogenic phenotypes. These results suggest that miR-31 may be a suppressor, the loss of which may promote lung carcinogenesis.
